NSAIDs vs. Coxibs in the Presence of Aspirin
Rheumatoid Arthritis, Cardiovascular Diseases
About this trial
This is an interventional basic science trial for Rheumatoid Arthritis
Eligibility Criteria
Inclusion Criteria:Qualified patients should have all 4 main criteria
- Age 18-75 years of age for patients who regularly use NSAIDs.
- Age 18-65 years of age for patients who do not regularly use NSAIDs
- Able to give informed consent
Subjects with CVD or increased CV risk. Please see definitions for each criteria below:
Increased CV risk (Subjects should have at least 3 of the following)
- > 55 years of age
- Hypertension
- Dyslipidemia (LDL > 160 mg/dL or HDL < 40 mg/dL in females and < 35 mg/dL in males or subjects currently receiving lipid lowering therapy as standard of care (i.e. statin drugs, prescription ω 3-acid ethyl esters, fibrates or prescription niacin [≥1,000 mg/d])
- Family history of premature CV disease (MI, angina pectoris, heart failure, cardiac death or coronary revascularization, stroke, carotid endarterectomy, or other arterial surgery or angioplasty for atherosclerotic vascular disease in a parent, grandparent, or sibling with symptom onset or diagnosis before age 55 y for males and 65 y for females)
- Current smoker
- Left ventricular hypertrophy
- Documented ankle brachial index of <0.9
- History of microalbuminuria, urine protein-creatinine ratio of >2
CV disease (defined as one of the following):
- Calcium score of >0
- ≥ 50 % occlusion of a coronary artery by angiography
- ≥ 50 % occlusion of a carotid artery by angiography or ultrasound
- History of stable angina
- Symptomatic peripheral arterial disease
- Prior MI, unstable angina, percutaneous coronary intervention, CABG, TIA, ischemic stroke, carotid endarterectomy, or other arterial surgery or angioplasty, which have occurred > 3 months prior to screening visit
- Diabetes Mellitus type 1 or 2 (considered a CV disease equivalent).
- Clinical diagnosis of rheumatoid arthritis, as determined by individual patient and physician, requiring daily treatment with NSAIDs.
Exclusion Criteria: Subjects with any of the following criteria will be excluded from this study:
- Unstable angina, MI, CVA, CABG <3 months from screening visit
- Planned coronary, cerebrovascular, or peripheral revascularization
- Undergone major surgery within 3 months prior to screening visit or has planned major surgery during the study period
- Uncontrolled hypertension (SBP >190, DBP >100 mm Hg) during screening visit
- Uncontrolled arrhythmia < 3 months from screening visit
- NYHA class III-IV heart failure or if available, ejection fraction ≤ 35 %
- Within 6 months prior to screening visit, a history of ACS or hospitalization for heart failure
- Oral corticosteroid, prednisone (or equivalent) > 20 mg daily
- Anticoagulation therapy
- Antiplatelet therapy except for aspirin
- GI ulceration < 60 days before screening visit
- GI bleeding, perforation, obstruction < 6 months of screening visit
- Inflammatory bowel disease, diverticulitis active < 6 months of screening visit
- AST, ALT, or BUN >2x the upper limit normal (within 30 days prior to screening visit)
- Creatinine level >1.7 mg/dL in men, 1.5 mg/dL in women (within 30 days prior to screening visit)
- On fluconazole, methotrexate, or lithium therapy
- Malignancy < 5 years before screening visit
- Other known, active, significant GI, hepatic, renal, or coagulation disorders
- Allergy, allergic-type reactions or hypersensitivity (e.g. asthma, urticaria, etc.) to any of the study medications and its components (i.e. sulfonamides)
- History of any disease of condition that, in the opinion of the investigator would place the subject at an unacceptable risk to participate in this study
- Any clinically relevant abnormal findings in physical examination, vital signs, or previous laboratory works that, in the opinion of the investigator, may compromise the safety of the subject to participate
- Subjects who are legally institutionalized
- Lactating females or females of childbearing potential except for those who are surgically sterile or postmenopausal-
Sites / Locations
- Inova Heart and Vascular InstituteRecruiting
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
ASA and Celecoxib
ASA and Naproxen
Take celecoxib 200mg capsule twice a day and aspirin 81mg tablet once a day for 4 weeks (after completion of the run-in period)
Take naproxen sodium 550mg tablet twice a day and aspirin 81mg tablet once a day (after completion of the run-in period)